Dr. David S. Dickens
Claim this profileUniversity of Iowa/Holden Comprehensive Cancer Center
Expert in Brain Tumor
Expert in Cancer
64 reported clinical trials
123 drugs studied
About David S. Dickens
Education:
- Earned an MD (Doctor of Medicine).
Experience:
- Serves as a Clinical Professor of Pediatrics at the University of Iowa.
- Holds the position of Clinical Director of Pediatric Oncology at the University of Iowa.
- UI Dance Marathon Endowed Chair in Pediatric Oncology, focusing on Clinical and Translational Research.
- Active Full Member of the Cancer Epidemiology and Population Science program at the University of Iowa Holden Comprehensive Cancer Center.
- Engaged in numerous clinical trials and research projects within pediatric oncology.
Area of expertise
1Brain Tumor
Global LeaderStage IV
Stage I
Stage II
2Cancer
Global LeaderStage I
Stage IV
Stage II
Affiliated Hospitals
Clinical Trials David S. Dickens is currently running
Selumetinib vs. Chemotherapy
for Brain Cancer
This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
Recruiting2 awards Phase 3
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
More about David S. Dickens
Clinical Trial Related8 years of experience running clinical trials · Led 64 trials as a Principal Investigator · 24 Active Clinical TrialsTreatments David S. Dickens has experience with
- Cyclophosphamide
- Radiation Therapy
- Etoposide
- Doxorubicin Hydrochloride
- Nivolumab
- Methotrexate
Breakdown of trials David S. Dickens has run
Brain Tumor
Cancer
Neuroblastoma
Lymphoma
Brain Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does David S. Dickens specialize in?
Is David S. Dickens currently recruiting for clinical trials?
Are there any treatments that David S. Dickens has studied deeply?
What is the best way to schedule an appointment with David S. Dickens?
What is the office address of David S. Dickens?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.